Wells Fargo’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-79
| Closed | -$35 | – | 7701 |
|
|
2024
Q1 | $35 | Hold |
79
| – | – | ﹤0.01% | 6943 |
|
|
2023
Q4 | $58 | Buy |
79
+14
| +22% | +$10 | ﹤0.01% | 6902 |
|
|
2023
Q3 | $56 | Buy |
65
+3
| +5% | +$4 | ﹤0.01% | 6894 |
|
|
2023
Q2 | $116 | Hold |
62
| – | – | ﹤0.01% | 6836 |
|
|
2023
Q1 | $229 | Sell |
62
-199
| -76% | -$919 | ﹤0.01% | 6741 |
|
|
2022
Q4 | $995 | Buy |
261
+200
| +328% | +$1.03K | ﹤0.01% | 6192 |
|
|
2022
Q3 | $0 | Buy |
61
+51
| +510% | +$844 | ﹤0.01% | 7621 |
|
|
2022
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 7733 |
|
|
2022
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 8064 |
|
|
2021
Q4 | $1K | Hold |
10
| – | – | ﹤0.01% | 7106 |
|
|
2021
Q3 | $1K | Hold |
10
| – | – | ﹤0.01% | 6840 |
|
|
2021
Q2 | $1K | Sell |
10
-304
| -97% | -$33.6K | ﹤0.01% | 6779 |
|
|
2021
Q1 | $46K | Sell |
314
-1,327
| -81% | -$240K | ﹤0.01% | 5853 |
|
|
2020
Q4 | $230K | Buy |
1,641
+133
| +9% | +$21.6K | ﹤0.01% | 5009 |
|
|
2020
Q3 | $229K | Buy |
1,508
+256
| +20% | +$41.8K | ﹤0.01% | 4892 |
|
|
2020
Q2 | $220K | Buy |
1,252
+1,220
| +3,813% | +$204K | ﹤0.01% | 4855 |
|
|
2020
Q1 | $4K | Buy |
+32
| New | +$4.23K | ﹤0.01% | 5912 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6836 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6811 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6685 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6554 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6671 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6637 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6641 |
|
|
2018
Q1 | – | Sell |
-2
| Closed | -$297 | – | 6626 |
|
|
2017
Q4 | $2K | Hold |
2
| – | – | ﹤0.01% | 6212 |
|
|
2017
Q3 | $1K | Hold |
2
| – | – | ﹤0.01% | 6253 |
|
|
2017
Q2 | $1K | Buy |
+2
| New | +$537 | ﹤0.01% | 6155 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6565 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6493 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6391 |
|
|
2016
Q2 | – | Sell |
-1
| Closed | -$1.26K | – | 6389 |
|
|
2016
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 6120 |
|
|
2015
Q4 | $2K | Sell |
1
-4
| -80% | -$6.14K | ﹤0.01% | 6033 |
|
|
2015
Q3 | $5K | Sell |
5
-5
| -50% | -$5.79K | ﹤0.01% | 5865 |
|
|
2015
Q2 | $10K | Buy |
10
+5
| +100% | +$5.39K | ﹤0.01% | 5820 |
|
|
2015
Q1 | $5K | Sell |
5
-2
| -29% | -$6.6K | ﹤0.01% | 5824 |
|
|
2014
Q4 | $23K | Hold |
7
| – | – | ﹤0.01% | 5310 |
|
|
2014
Q3 | $20K | Sell |
7
-20
| -74% | -$66.2K | ﹤0.01% | 5307 |
|
|
2014
Q2 | $104K | Buy |
27
+9
| +50% | +$33.9K | ﹤0.01% | 4664 |
|
|
2014
Q1 | $96K | Buy |
18
+17
| +1,700% | +$89.5K | ﹤0.01% | 4672 |
|
|
2013
Q4 | $3K | Hold |
1
| – | – | ﹤0.01% | 5495 |
|
|
2013
Q3 | $3K | Hold |
1
| – | – | ﹤0.01% | 5398 |
|
|
2013
Q2 | $3K | Buy |
+1
| New | +$3.21K | ﹤0.01% | 5329 |
|
Other funds holding NBSE
Wells Fargo's NBSE Position: Q2 2024 in Review
Wells Fargo sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 79 shares — an estimated $35 sold.
Wells Fargo first reported a position in NBSE in Q2 2013 and held it in 32 quarters. The position peaked at $230K in Q4 2020. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- Wells Fargo reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 79 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $35.
- Wells Fargo first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2013 and held it in 32 quarters.
- Wells Fargo's NeuBase Therapeutics, Inc. Common Stock position peaked at $230K in Q4 2020.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.